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The incidence of hepatocellular carcinoma (HCC) has
increased in recent years, not only in Asia and in Africa,
where it is the second leading cancer, but also in Europe and
the USA (1). Most HCC cases occur in patients with
advanced chronic liver disease related to chronic hepatitis
C virus (HCV) infection, chronic hepatitis B (HBV) infection
or alcohol abuse. In the last decade, an increasing number of
publications have reported an association between nonalco-
holic fatty liver disease (NAFLD) and HCC (2).
We recently reported on a series of 42 patients with HCC
related to either NAFLD or to cryptogenic cirrhosis and
showed that the patients were older, predominantly male
(62%) and commonly (81%) had metabolic syndrome risk
factors, such as obesity, diabetes, hypertension, or dyslipi-
demia. We found evidence of cirrhosis in 38 patients (90%),
either through liver biopsy or based on clinical signs /
symptoms. The diagnosis of HCC was achieved through a
screening program in 55% of the 42 patients (3).
In a robust study assessing the epidemiology and
surveillance of patients with HCC in the USA, Younossi et
al. found that the prevalence of HCC in patients with
NAFLD increased by 9% over a six-year of the evaluation
period (2004-2009). They also reported that NAFLD
increased the risk of 1-year mortality and that it will be a
major cause of HCC in the USA (2).
In our Liver Transplant Unit, HCFMUSP, we transplanted
123 patients with HCC over the past 4 years. Six patients
(4.9%) had a previous diagnosis of NAFLD. Seven of the
cases (5.7%) had cryptogenic cirrhosis. In these cases, the
average BMI was 26.3, but 25% had a BMI higher than
28 and 10% had a BMI over 32. Diabetes was present in
29.3% of the patients. These data contrast with reference to
NASH, as only 1.9% of a previous cohort of patients with
HCC also presented with NASH (our unpublished data).
In a recent issue of CLINICS, Cotrim et al. (4) reported on a
Brazilian survey of 110 HCC cases with NAFLD from nine
hepatology units in six Brazilian states. Similar to the
findings from Younossi et al. (2), these patients were older
(mean age=67 years), and 65.5% were male. Obesity was
observed in 52.7% of the cases, diabetes in 73.6%, dyslipi-
demia in 41.0%, hypertension in 60% and metabolic
syndrome in 57.2%.
The nature of a national survey imparts some limitations.
For example, there is heterogeneity in the methods used to
acquire clinical and laboratorial data, there is no standardi-
zation of therapeutic procedures and there is no patient
follow-up. Even so, this survey was successful in providing
insight into the growing prevalence of patients with NASH
in Brazil. It also highlighted the need to standardize clinical
data regarding not only the potential for progression to
cirrhosis but also the actual possibility of development of
HCC, including for patients with NASH without fully
developed cirrhosis. These data, aligned with our own
experience, have caused our group to debate the need to
survey patients with NASH even before cirrhosis is fully
developed. Our main concern in this regard is the excess
workload for ultrasonographists, whereas performing other
imaging methods would be excessively expensive.
In a study reported by Cotrim et al. (4), histological
diagnosis of HCC was performed in 47.2% of patients. Out of
48 cases where non-tumoral samples were available for
histopathological study, NASH-related cirrhosis was diag-
nosed in 32 cases (66.7%), NASH + fibrosis (grade 1-3) was
diagnosed in 14 cases (29.1%) and NASH without fibrosis
was diagnosed in 2 cases (4.2%). Brazilian clinicians,
radiologists and surgeons have also biopsied liver nodules
and non-neoplastic livers, which has further improved
understanding of the heterogeneity of the clinical and
pathological settings that foster HCC development. Careful
follow-up of patients also enables better selection of high-risk
patients, who should undergo surveillance procedures, as
recently reported by Vezozzo et al. (5). As in recent years,
liver biopsy has become highly valued for addressing major
questions related to hepatocarcinogenesis (6,7), more colla-
borative studies involving multidisciplinary Brazilian study
groups to identify further associations between epidemiolo-
gical and clinical variables and morphological and molecular
biomarkers are expected in the future.
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